Stock TLSA TIZIANA LIFE SCIENCES LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.775 USD +2.84% Intraday chart for Tiziana Life Sciences Ltd +40.78% +38.39%
Apr. 23 Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Apr. 23 Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Rise in Afternoon Trading
MT
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program
MT
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
AQ
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today
AQ
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
AQ
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program
CI
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
AQ
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
AQ
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology
CI
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
CI
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
AQ
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
AQ
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
AQ
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
CI
Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity
MT
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
AQ
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
AQ
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
CI
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Tiziana Life Sciences : Updated Interim Results for the Six Months Ended 30 June 2023 - Form 6-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLSA Stock
  4. News Tiziana Life Sciences Ltd